Bifogade filer
PDF
Beskrivning
| Land | Finland |
|---|---|
| Lista | Spotlight |
| Sektor | Handel & varor |
| Industri | Detaljhandel |
Eevia Health ("Eevia" or "The Company") received a KSEK 638 / KUSD 59 sales order draw for the elderberry extract Feno-Sambucus™ 7 ORGANIC from a US customer.
The end customer is a young brand owner within organic supplements and health products. The sales order is from Select Ingredients, a company working out of San Diego, California, US. Select Ingredients specializes in organic ingredients and high-quality natural plant extracts and serves branded customers in the Golden State and other large US states.
The order is for Feno-Sambucus™ 7 ORGANIC, an organically certified elderberry extract with a standardized level of anthocyanins that complies with key monographs, such as the United States Pharmacopeia. However, due to Eevia's production and purification approach, the product contains more other polyphenols than comparable extracts. It is documented in pre-clinical vivo testing in 138 biomarkers that Eevia's extract has a better bioactivity performance than similar competing products.
The sales value in euros is KEUR 56 (KSEK 638) FCA Finland and the order is a repeat order from the end customers.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing biomaterials that may dramatically impact human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.